Maurer Alan H, Elsinga Philip, Fanti Stefano, Nguyen Binh, Oyen Wim J G, Weber Wolfgang A
Department of Radiology, Temple University Hospital and School of Medicine, Philadelphia, Pennsylvania.
J Nucl Med. 2014 May;55(5):701-4. doi: 10.2967/jnumed.113.133074. Epub 2014 Apr 14.
Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. (99m)Tc-etarfolatide, a (99m)Tc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.
叶酸受体(FR)可作为治疗靶点,因为它在不同的上皮癌中表达,如卵巢癌、非小细胞肺癌、子宫内膜癌和乳腺癌。评估肿瘤中的FR表达可能有助于识别能够从FR靶向治疗中获益的患者,如维替泊芬和法勒图珠单抗。存在多种检测FR表达的方法。组织采样的临床效用有限,主要是因为它需要侵入性操作。(99m)Tc-依他福肽,一种(99m)Tc标记的叶酸偶联物,正在欧美进行后期试验。它可以对FR进行无创全身成像。本综述重点关注这种FR成像剂及其如何用于指导FR靶向治疗。